MODERN APPROACHES TO THE PHARMACOKINETICS AND PHARMACODYNAMICS OF ANTISEIZURE MEDICATIONS IN PATIENTS WITH EPILEPSY

Authors

Keywords:

epilepsy; antiseizure medications; pharmacokinetics; pharmacodynamics; therapeutic drug monitoring; pharmacogenetics; drug interactions; precision medicine; population pharmacokinetics; individualized therapy.

Abstract

Epilepsy is a chronic neurological disorder characterized by a persistent predisposition to epileptic seizures. Antiseizure medications (ASMs) are the principal pharmacological treatment, but their clinical performance is determined by a complex relationship between drug exposure, molecular targets, seizure biology, comorbidities, adherence and patient-specific pharmacokinetic variability. This narrative review examines contemporary pharmacokinetic and pharmacodynamic principles relevant to commonly used ASMs and emphasizes how these principles can be translated into individualized treatment. Particular attention is given to absorption, distribution, protein binding, hepatic and renal elimination, nonlinear kinetics, enzyme induction and inhibition, therapeutic drug monitoring, pharmacogenetics, pregnancy-associated changes, and model-informed precision dosing. Traditional ASMs such as carbamazepine, phenytoin, phenobarbital and valproate remain clinically useful but present substantial interaction and exposure–response challenges. Newer agents such as levetiracetam, brivaracetam and lacosamide generally offer more predictable pharmacokinetics and fewer interactions, although clinically relevant limitations remain. Therapeutic drug monitoring is most useful when there is a defined clinical question rather than as an isolated numerical target. Pharmacogenetic testing has its strongest current clinical role in predicting severe cutaneous reactions associated with selected aromatic ASMs and in supporting phenytoin dose optimization in genetically susceptible patients. Pregnancy illustrates the importance of dynamic monitoring because clearance and concentration-to-dose relationships may change substantially for several ASMs. Population pharmacokinetic models, Bayesian forecasting, microsampling, pharmacogenomics and digital adherence tools are emerging components of precision epilepsy care. Overall, modern ASM management should integrate seizure classification, pharmacodynamic mechanism, pharmacokinetic behavior, interaction burden, organ function, reproductive considerations and patient-specific therapeutic response.

 

References

1.Barguilla A, Riera P, Ros-Castelló V, Muino E, Sierra-Marcos A. Pharmacogenomics of anti-seizure medications in epilepsy: a systematic review of genetic predictors of response and tolerance. Expert Rev Neurother. 2026;26(5). doi:10.1080/14737175.2026.2647028.

2.Beghi E. The epidemiology of epilepsy. Neuroepidemiology. 2020;54(2):185-191. doi:10.1159/000503831.

3.Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2013;54(1):11-27. doi:10.1111/j.1528-1167.2012.03671.x.

4.Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475-482. doi:10.1111/epi.12550.

5.Johannessen Landmark C, Eyal S, Burns ML, Franco V, Johannessen SI. Pharmacological aspects of antiseizure medications: from basic mechanisms to clinical considerations of drug interactions and use of therapeutic drug monitoring. Epileptic Disord. 2023;25:454-471. doi:10.1684/epd.2023.1555.

6.Karnes JH, Rettie AE, Somogyi AA, Huddart R, Fohner AE, Formea CM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and HLA-B genotypes and phenytoin dosing: 2020 update. Clin Pharmacol Ther. 2021;109(2):302-309. doi:10.1002/cpt.2008.

7.Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser WA, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069-1077. doi:10.1111/j.1528-1167.2009.02397.x.

8.Li Y, Wang ML, Guo Y, Cao YF, Zhao MM, Zhao LM. Population pharmacokinetics and dosing regimen optimization of levetiracetam in epilepsy during pregnancy. Br J Clin Pharmacol. 2023;89(3):1152-1161. doi:10.1111/bcp.15572.

9.Manson LEN, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Houwink EJF, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs. Eur J Hum Genet. 2024;32(8):903-911. doi:10.1038/s41431-024-01572-4.

10.Patsalos PN, Berry DJ, Bourgeois BFD, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239-1276. doi:10.1111/j.1528-1167.2008.01561.x.

11.Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit. 2018;40(5):526-548. doi:10.1097/FTD.0000000000000546.

12.Perucca E, French JA, Aljandeel G, Balestrini S, Braga P, Burneo JG, et al. Which terms should be used to describe medications used in the treatment of seizure disorders? An ILAE position paper. Epilepsia. 2024;65(3):533-541. doi:10.1111/epi.17877.

13.Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61(3):246-255. doi:10.1111/j.1365-2125.2006.02529.x.

14.Phillips EJ, Sukasem C, Whirl-Carrillo M, Müller DJ, Dunnenberger HM, Chantratita W, et al. Clinical Pharmacogenetics Implementation Consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update. Clin Pharmacol Ther. 2018;103(4):574-581. doi:10.1002/cpt.1004.

15.Schoretsanitis G, Deligiannidis KM, Kasperk N, Schmidt CT, Kittel-Schneider S, Ter Horst P, et al. The impact of pregnancy on the pharmacokinetics of antiseizure medications: a systematic review and meta-analysis of data from 674 pregnancies. Prog Neuropsychopharmacol Biol Psychiatry. 2024;133:111030. doi:10.1016/j.pnpbp.2024.111030.

16.Spina E, Barbieri MA, Alborghetti M, Nicoletti F, de Leon J. An update on the pharmacokinetic and pharmacodynamic interactions between antidepressants and antiseizure medications. Expert Opin Drug Metab Toxicol. 2026;22(4):267-287. doi:10.1080/17425255.2026.2650188.

17.U.S. Food and Drug Administration. Table of pharmacogenetic associations [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2026 [cited 2026 Sep 13]. Available from: https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations.

18.Yang X, Sun Y, Hua Z, Li T, Li X, Du P. Safety of valproic acid use in pregnant women: a systematic review and meta-analysis. J Obstet Gynaecol Res. 2025;51(11):e70121. doi:10.1111/jog.70121.

Published

2026-09-21